Top Markets
Coin of the day
Valbiotis SA Valbiotis SA

Valbiotis SA

ALVAL
Rangering i aksjer #16324
Valbiotis SA engages in the research and development of health nutrition... Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.
Aksjekurs
$0.94180721
Markedsverdi
$22.26M
Endring (1 dag)
0.38%
Endring (1 år)
-14.35%
Land
FR
Handel Valbiotis SA (ALVAL)

Kategori

EPS for Valbiotis SA (ALVAL)
EPS per December 2025 TTM: $-0.57
Ifølge de siste økonomiske rapportene og aksjekursen til Valbiotis SA er selskapets nåværende EPS (TTM) $-0.57. Ved slutten av 2023 hadde selskapet en EPS på $-0.65, en nedgang sammenlignet med EPS-en i 2022 som var $-1.31.
EPS-historikk for Valbiotis SA fra 2015 til 2026
EPS ved slutten av hvert år
År EPS Endre
2026 (TTM) $-0.57 -12.89%
2024 $-0.66 0.52%
2023 $-0.65 -50.16%
2022 $-1.31 21.14%
2021 $-1.08 73.93%
2020 $-0.62 -52.69%
2019 $-1.31 -13.46%
2018 $-1.52 37.41%
2017 $-1.10 517.05%
2016 $-0.18 -99.73%
2015 $-65.94 0.00%
EPS for lignende selskaper eller konkurrenter
Selskap EPS EPS-forskjell Land
$4.36 -858.10%
DK
$17.01 -3,058.78%
US
$42.53 -7,497.81%
US
$9.62 -1,773.47%
BE
$23.88 -4,253.77%
NL